Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment

Table 1 Ongoing clinical trials of other TKIs as single agents for HCC

Trial	Identifier	Study arm	Phase	Enrolment	Primary endpoint	State
N/A	NCT02508467	Fisogatinib (BLU-554)	1	150	Safety	Active, not recruiting
NTAHCC	NCT03950518	Anlotinib Hydrochloride; Anlotinib Hydrochloride Capsules; Anlotinib;Levamisole	3	300	PFS	Recruiting
N/A	NCT04985136	Camrelizumab + rivoceranib; sorafenib; regorafenib; rivoceranib	3	482	Stage I: ORR; stage II: OS	Enrolling by invitation
N/A	NCT03945799	Anlotinib hydrochloride	1/2	60	DFS	Recruiting
N/A	NCT01737827	INC280	2	38	Time to progression per RECIST 1.1	Active, not recruiting
JAKaL	NCT04358185	Itacitinib	1	25	AE; ORR	Recruiting
N/A	NCT03582618	Foslinanib + sorafenib	2	40	ORR	Active, not recruiting
N/A	NCT03941873	Sitravatinib; sitravatinib + tislelizumab	1/2	111	AE; SAE per NCI-CTCAE 5.0	Active, not recruiting
AFHC	NCT04954521	Anlotinib	N/A	200	PFS	Recruiting
N/A	NCT05070247	TAK-500	1	106	TEAE grades per NCI CTCAE 5.0; AE; SAE	Not yet recruiting
N/A	NCT03195699	TTI-101	1	60	Safety	Recruiting

PFS progression free survival, DFS disease free survival, RECIST response evaluation criteria in solid tumours, CTCAE common terminology criteria for adverse events, TEAT treatment emergent adverse events, NCI national cancer institute, AE adverse events, SAE serious adverse events

ISSN: 1475-2867